ライフサイエンスコーパス: hepatocellular cancer

1 tage liver diseases, including cirrhosis and hepatocellular cancer.

2 iated thyroid cancer compared with renal and hepatocellular cancer.

3 mpared with sorafenib experience in renal or hepatocellular cancer.

4 pathways and/or intermediate stages, such as hepatocellular cancer.

5 most common primary hepatic malignancy after hepatocellular cancer.

6 ll cycle progression, and ultimately lead to hepatocellular cancer.

7 ir potential therapeutic application against hepatocellular cancer.

8 reatic cancer, and 9204 patients (2.6%) with hepatocellular cancer.

9 e linked to hepatic steatosis, fibrosis, and hepatocellular cancer.

10 ing cirrhosis to differentiate lymphoma from hepatocellular cancer.

11 gase complex, is overexpressed in breast and hepatocellular cancers.

12 encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14).

13 nic liver failure (4 patients), and solitary hepatocellular cancer (1 patient) were the main indicati

14 HE (7 patients) and hepatocellular cancer (2 patients) were confounding diag

15 he HCV cohort (P = 0.03), including incident hepatocellular cancer (6 versus 18; P = 0.03), but that

16 18 colorectal cancer, 11 melanoma cancer, 10 hepatocellular cancer, 8 sarcoma cancer, and 25 other ca

17 (UNOS) status of recipient, and presence of hepatocellular cancer affected the outcome of OLT.

18 For recurrence of hepatocellular cancer after hepatic resection or local a

19 gression to advanced disease, cirrhosis, and hepatocellular cancer and are more likely to develop liv

20 ggressive hepatobiliary malignancies such as hepatocellular cancer and cholangiocarcinoma, are associ

21 oplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma.

22 fy TICs of various tumor entities, including hepatocellular cancer and glioblastoma.

23 Aflatoxin promotes hepatocellular cancer, and fumonisin may promote esophag

24 with advanced renal-cell carcinoma (RCC) or hepatocellular cancer, and its application in other type

25 atic tumors such as hepatocellular adenomas, hepatocellular cancers, and hepatoblastomas have mutatio

26 curs during liver growth in hepatoblastomas, hepatocellular cancers, and liver regeneration.

27 Decompensated cirrhosis and hepatocellular cancer are major risk factors for mortali

28 tation because of end-stage liver disease or hepatocellular cancer as well as in posttransplant phase

29 opriate, affordable, and early cirrhosis and hepatocellular cancer care to prevent the need for LT.

30 man Caucasian lung carcinoma cells and human hepatocellular cancer cell line cells, nanomolar concent

31 vidence of elevated frequency in bladder and hepatocellular cancer cells.

32 cence modulators, can also function in human hepatocellular cancer cells.

33 Hepatocellular cancer deaths were positively related to

34 sociated with faster entry into S phase, and hepatocellular cancer formation.

35 rectal, esophageal, gastric, pancreatic, and hepatocellular cancer from 1990 to 2016.

36 ue-specific gastrointestinal cancers such as hepatocellular cancers, gastric adenocarcinomas, and col

37 Patients with hepatocellular cancer had the lowest cardiac-specific me

38 associated with survival after recurrence of hepatocellular cancer (HCC) after resection and the outc

39 BACKGROUND AND AIMS: The risk of hepatocellular cancer (HCC) after sustained virological

40 DD45beta has been verified to be specific in hepatocellular cancer (HCC) and consistent with the p53

41 ) exception points provided to patients with hepatocellular cancer (HCC) are not based on outcome dat

42 Hepatoblastoma (HBL) and hepatocellular cancer (HCC) are the most common primary

43 e evaluated the expression of miRNA in human hepatocellular cancer (HCC) by expression profiling, and

44 termined TP73 expression in HepCY and HepCO, hepatocellular cancer (HCC) cell lines (HepG2, SNU398, S

45 xpression was markedly reduced in four human hepatocellular cancer (HCC) cell lines compared with nor

46 dergoing liver transplantation for stage 1-2 hepatocellular cancer (HCC) have an excellent long-term

47 Hepatocellular cancer (HCC) is an established indication

48 Hepatocellular cancer (HCC) is the fifth most common sol

49 Hepatocellular cancer (HCC) is the fourth leading cause

50 y in vivo, in HLA-A*0201+AFP+ advanced stage hepatocellular cancer (HCC) patients, and have activated

51 n effective therapeutic approach to overcome hepatocellular cancer (HCC) resistance to immune checkpo

52 Examination of human hepatocellular cancer (HCC) reveals cells that label wit

53 ing (n = 7), hepatic encephalopathy (n = 4), hepatocellular cancer (HCC) screening (n = 1), liver tra

54 atively available variables in patients with hepatocellular cancer (HCC) waiting for liver transplant

55 ut the best approach to select patients with hepatocellular cancer (HCC) waiting for liver transplant

56 t 40% of elf(+/-) mice spontaneously develop hepatocellular cancer (HCC) with markedly increased cycl

57 ng contributes to fibrotic liver disease and hepatocellular cancer (HCC), both of which are associate

58 ral agents (DAAs) holds promise for reducing hepatocellular cancer (HCC).

59 patitis (NASH) may progress to cirrhosis and hepatocellular cancer (HCC).

60 fide tumor suppressor, is down-regulated in hepatocellular cancer (HCC).

61 tions in DNA methylation frequently occur in hepatocellular cancer (HCC).

62 pathway is implicated in the pathogenesis of hepatocellular cancer (HCC).

63 expression of ultraconserved RNAs (ucRNA) in hepatocellular cancer (HCC).

64 ( CTNNB1 ) mutations are seen in 30% of all hepatocellular cancer (HCC).

65 FRalpha) signaling is evident in a subset of hepatocellular cancers (HCCs).

66 however, is observed in a subset of primary hepatocellular cancers (HCCs).

67 and ligand expression is frequently seen in hepatocellular cancers (HCCs).

68 sessed in mice bearing human PlGF-expressing hepatocellular cancer (Huh7) xenografts or human renal c

69 n liver disease progression and promotion of hepatocellular cancer in HCV-G3.

70 to link tamoxifen with an increased rate of hepatocellular cancer in humans; the contrasting carcino

71 The recent increase in the incidence of hepatocellular cancer in the United States is thought to

72 impaired VLDL secretion in Mttp-LKO mice on hepatocellular cancer incidence and progression in compa

73 status was not independently associated with hepatocellular cancer (IRR = 0.96; 95% CI, 0.56 to 1.63)

74 Hepatocellular cancer is a highly vascular tumor, where

75 Screening for hepatocellular cancer is justified.

76 Hepatocellular cancer is notorious for recurrence even a

77 s, also having a higher risk of noncirrhotic hepatocellular cancer, is likely to accelerate the accep

78 V1-TK has been demonstrated in the livers of hepatocellular cancer patients.

79 th pancreatic, biliary, esophagogastric, and hepatocellular cancers, resistance to conventional thera

80 Importantly, hepatocellular cancer spontaneously developed in 75% of

81 However, many details about hepatocellular cancer stem cells that are important for

82 e for the TGF-beta signaling pathway in both hepatocellular cancer suppression and endoderm formation

83 wer rates of liver-related complications and hepatocellular cancer than corresponding patients with H

84 e beta-catenin), regenerating livers, and in hepatocellular cancer tissues that exhibit beta-catenin

85 ) is expressed by stem-like and poor outcome hepatocellular cancer tumors and is a clinical tumor bio

86 eiving Vitamin K2, pooled relative risks for hepatocellular cancer were 0.60; 95% CI: 0.28-1.28, p =

87 This strategy is particularly relevant to hepatocellular cancer, which is treated clinically with

88 is also associated with an increased risk of hepatocellular cancer, which may occur even in the absen

89 MORV was shown to be efficacious in a Hep3B hepatocellular cancer xenograft model but not in a CCA x